C ORONARY thrombosis kills at least 200,000 people a year in the United States, and this figure will increase inexorably as the average age of our population continues to increase. It occurs in all ages but is predominantly encountered in persons over the age of 40 . In general, it may be said that coronary thrombosis occurs at an average age which is approximately 6 years younger in men than in women. More men than women suffer and die from it in every age group under the age of 80. It has been encountered in infants as young as 3 months. One of the most unfortunate characteristics of this disease is that it strikes down many persons at the height of their productive years and activity, at times when they have the greatest responsibilities toward their communities and their families. It is a problem of increasing importance in national and community life.
The underlying process responsible for this condition is almost invariably arteriosclerosis, frequently a special type of intimal atherosclerosis. There are rare instances in which narrowing of a coronary artery has occurred either as a result of some other disease process or as a congenital anomaly, or in which myocardial infarction has occurred as a result of overstrain without adequate blood supply to an area of the myocardium. But such situations are so infrequent that for purposes of this discussion they may be ignored. The usual sequence is that arteriosclerotic plaques narrow the lumen of the coronary artery to such a degree that a thrombosis eventually occurs. This in turn produces the sudden occlusion which results in marked ischemia of the muscle, with subsequent necrosis and a profound effect on the efficiency of the heart muscle. This may occur as a result of occlusion of a small branch of the coronary tree, in which case recovery is very likely to occur. On the other hand, it may be a very extensive process involving a large 0YOCARDRIAL INFARCTION IN CORONARY THROMBOSIS original insult. These phenomena may include: (1) Subsequent extension of the original thrombus to block off additional arteries or branches of the artery which was primarily involved.
(2) Involvement of some other branch of the coronary tree which further embarrasses the heart action. (3) The development of mural thrombi, attached to the endocardium at the location of the original infarction, which are capable of releasing emboli to various parts of the body, either from the right side or the left side of the heart depending upon the location of the mural thrombus. (4) The development of thromboses elsewhere in the body, particularly in the veins of the legs, which are in turn capable of producing fatal and nonfatal emboli. There is one exception to this ruling. There are many patients who have great difficulty in using the bed pan. It is the author's belief, and that of many others, that the use of a commode by the bedside, with the assistance of nurses and orderlies, may require much less effort on the part of the patient than the use of a bed pan. A commode is therefore recommended as soon as the patient appears to be able to make the short move from the bed which is required. Most patients are extremely grateful for this accommodation. After a period of from three to eight weeks, depending on the condition of the patient and the reaction of his pulse to the initiation of activity, he should begin to sit up in bed and exercise, using the arms and legs quietly at first. Finally, lie is moved from the bed to a chair and gradually begins to assume increasing activity. The pulse is watched very carefully during this period. A pulse rate exceeding 100 means that exercise should be discontinued for the time being, to be started again after a period of rest. Dyspnea is also evidence that the patient should not force activity without further rest.
2. Sedation. Patients with coronary throm bosis usually suffer from marked apprehension and extreme nervousness, both at the time of their attack and subsequent to it. This cannot but aggravate the situation since the release of adrenaline and nervous stimuli tend to increase vasoconstriction. The sedatives of choice still remain morphine sulfate given in doses of 0.015 grams, the precise amount depending on the degree of pain suffered by the patient; Pantopon, 0.02 gram, appears to produce less nausea than does morphine in many people. These drugs are preferably given by hypodermic, because nausea is frequently present and an oral narcotic may not be adequately absorbed. Papaverine, 0.1 grams given intravenously, may also be administered for severe pain but sometimes produce disagreeable side reactions. As Gold, Prinzmetal, and others have shown that transfusions of plasma or whole blood are useful to combat shock in the care of these patients. Prinzmetal demonstrated in animals that, if the heart muscle is weak and herniating as a result of insufficient blood, the addition of fresh blood or plasma may reduce the tendency towards herniation within a very short time. The restoration of blood pressure and general tone which is observed in patients suggests that a not dissimilar procedure may take place in human beings, although this cannot be regarded as definitely established at present. When transfusions are given the amount should probably be not more than 250 to 300 cc. This procedure may be repeated in four hours. Whenever patients are receiving fluids intravenously they must be under continuous observation.
6. Other Drugs. In general, it is no longer considered good practice to give digitalis in the treatment of coronary thrombosis with myocardial infarction unless there is pronounced evidence of cardiac failure and the status appears to be deteriorating. The question has been debated widely but at present this position is regarded as justified. If digitalis is to be administered, it may be given in the form of extract of digitalis, powdered digitalis, digitoxin, or other glucosides having a similar action. The dosage should be sufficient to produce satisfactory digitalization but it is our impression that it is less hazardous to digitalize with moderate rapidity than by using a single massive dose.
Quinidine should be used in case of paroxysmal ventricular tachycardia. Some cardiologists also use it in the presence of evidence of cardiac irritability such as numerous premature beats. Under these circumstances, the dosage is 0.3 gram three to five times a day. In extreme conditions, this dosage may be doubled.
While aminophylline has been used the evidence that it has altered the mortality in any significant. fashion is, in our opinion, inconclusive. If it is desired to administer it, with the hope that it will serve as a coronary vasodilator or for any other reason, it should be given in dosages of 0.25 gram intravenously every four to six hours. It should be administered slowly, preferably as a drip infusion in 100 cc. of a solution of sodium chloride or glucose in distilled water. There have been some fatalities resulting from the rapid injection of aminophylline in patients who were doubtless sensitive to the drug.
There have also been advocates of the use of atropine, 1 mg. every four hours, in the treatment of coronary thrombosis. Here, also, there is inconclusive evidence of a demonstrable beneficial effect. A definite indication for its use exists, however, when carotid sinus hypersensitivity is present.
THE USE OF ANTICOAGULANTS 1. Experimental and Clinical Results. As early as 1938, Solandt and Best reported animal experiments in which coronary thrombosis was produced by isolating the coronary artery and injecting sodium ricinoleate into its lumen. The injected material was kept in contact with the intima for 5 minutes and the clamps on the vessel were then released. Thrombosis developed in almost every case in which heparin was not used whereas, in a corresponding study in which heparin was used, it was almost never observed. Solandt, Nassim, and Best continued their studies by producing intracardiac mural thrombi and, in turn, preventing their formation by the administration of heparin. In these latter experiments, a technic was evolved by which large mural thrombi could be regularly reproduced in the lumen of the left ventricle: its endocardium was injured by injecting sodium ricinoleate, and the myocardium was damaged by ligating the anterior descending branch of the left coronary artery. When heparin was not used, there was rapid formation of a thrombus, but none was seen in those experiments in which heparin was given before the injury was produced. The results of these studies left no doubt that under certain experimental conditions the effect of heparin in preventing thrombosis could be readily demonstrated.
Following these studies, sporadic efforts were made to use heparin in the treatment of clinical coronary thrombosis but as far as is known no large, well-controlled series were conducted because of the difficulties of continued heparinization. The question of increasing hemorrhage in the intima was also raised, although more as a theoretic than a proved risk. Following the early clinical use of dicumarol, it was used in a few patients with coronary thrombosis and myocardial infarction. The author began the study of dicumarol in the treatment of coronary thrombosis during May, 1942. After three and one-half years of experience involving 80 patients, the following conclusions seemed waranted. The use of dicumarol had not aggravated the condition in any patient. It appeared physiologically sound to give anticoagulant therapy when (1) there was a tendency for propagation of the original thrombus, (2) multiple thrombi tended to form in the coronary arteries or elsewhere, and (3) one or more emboli had occurred. The thromboembolic processes appeared to have been interrupted. There was no evidence that thrombi, once formed, had been dissolved. The progression of established infarctions did not appear to be interrupted. The rate and rhythm of the heart was not directly affected. These results were reported in December, 1945 per hundred cases in the control and treated groups show-ed a highly significant difference. Secondary myocardial extensions occurred in 9.7 per cent of the control group but only in 3.2 per cent of the treated group. New infarcts occurred in 6.1 per cent in the control as contrasted with 1.9 per cent in the treated group. Pulmonary emboli were encountered in 11.6 per cent in the controls against 4.8 per cent in the treated group. Cerebral emboli were diagnosed in 4.9 per cent of the controls but only in 0.7 per cent of the treated group. Peripheral emboli occurred in 2.7 per cent of the controls as compared with 0.5 per cent of the treated group. Venous thrombosis developed in 6.8 per cent of the control group and in 2.0 per cent of the treated group. The review' of these figures, which will appear in the final report of the Committee on Anticoagulants, demonstrates conclusively that the administration of anticoagulants produces a marked reduction in death rate from coronary thrombosis and has an even greater effect in preventing thromboembolic complications. These complications cannot be regarded lightly since they leave some patients hopeless hemiplegics, others with the loss of one or more limbs by amputation, or with similarly serious disabilities.
In the light of these figures and of an extensive experience with the use of anticoagulants, it is difficult to avoid the conclusion that anticoagulants should be administered to every patient suffering from an acute coronary thrombosis unless the definite contraindications which will be subsequently mentioned are present. On the other hand, as is widely recognized, anticoagulant drugs are not without their hazards. They, like most other forms of medical treatment, require skill and knowledge of the technic for their use. The incidence of bleeding which occurred per hundred cases in the series under discussion should be considered. In the control group, episodes of bleeding occurred 5.9 times in each hundred cases. This incidence was a surprise to some physicians who had assumed that bleeding was an uncommon occurrence in coronary thrombosis. The episodes included hematuria, epistaxis, and numerous other minor evidences of bleeding. In the treated group, there were a total of 15 The anticoagulants, dicumarol and heparin, were first used experimentally and, thereafter, clinical experience seemed to justify their more general acceptance in practice. In the case of these drugs, however, another step of importance was taken. The Committee on the Evaluation of Anticoagulants in the Treatment of Coronary Thrombosis With Myocardial Infarction studied 1,031 cases under a statistically valid program. Approximately one-half of these received the best available type of treatment used prior to anticoagulant therapy; the other half received anticoagulant therapy in addition. The results were strongly in favor of the use of anticoagulants in the sense that both the death rate and the incidence of complications were decreased. A brief summary of these findings has been presented above. On the basis of this study the more general use of anticoagulants in the treatment of this serious disease is recommended. It is also suggested that other drugs be subjected to similarly controlled studies before they are accepted by the medical profession as being of established value. ADDENDUM Since this paper was prepared, Tromexan, another coumarin, has become available. It acts more quickly than dicumarol (18 to 24 hours) and does not have so lasting an effect. The dosage is five or six times that required for dicumarol, and administration of the drug must be controlled by the prothrombin time determination. Further reports evaluating Tro- 
